Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IM Cannabis Corp C.IMCC

Alternate Symbol(s):  IMCC

IM Cannabis Corp. is a Canada-based international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel. In Germany, the Company operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. It offers four different product lines, leading with the Craft Collection which offers the highest quality Canadian craft cannabis flower. The Company's other product lines include Top-Shelf Collection, Signature Collection and Full Spectrum Extracts. The Company's brands include The WAGNERS, BLKMKT, LOT420, and The PICO collection (minis).


CSE:IMCC - Post by User

Comment by RockMaschineon Nov 04, 2021 2:33pm
153 Views
Post# 34088072

RE:Dilution

RE:Dilution
$4.7 million on a market cap of $200 million is negligible considering Panaxia will likely do double the revenue they paid for it. As of the most recent statement the total shareholder equity was listed at $200 million. This is trading a pretty much book value. Next quarter we'll see how much of the accounts receivable they've collected coupled with probably $10 million attributable to Highland Grow alone. I'm a bit concerned they haven't issued as statement regarding JWC product recall (a negative) or that they have successfully received several hundred kilos of product from qualified CDN LPs for Israel distribution (a positive). Israel is pushing forward with its medical program and I expect recreational reform inside of 2 years. Many industry insiders report even further progress. My tune would be different if I was holding a large position underwater; I'm not. Continuing to accumulate as the ground work is still being laid. Read up and learn how no large institutions are allowed to buy cannabis stocks. You have the likes of Creso, GTII and Trulieve doin $80-150+ million a quarter and these are valued at $2-5 billion. If you can't get past your paper losses and recognize the long, and I mean long as in 5 year plus opportunity I can't save you.
<< Previous
Bullboard Posts
Next >>